20/20 Biolabs, Inc.
AIDX · XNASCIK 1139685fmd_0W17HY5RMVE5NX6MDQEER8QXT7Services · Services-Testing LaboratoriesTemplate: Standard
Coverage: Jan 01, 2024 to Jun 30, 2026, 6 periods
| Line item | FY2024 | FY2025 |
|---|---|---|
| Total revenues | 2 | 2 |
| Cost of revenue | 1 | 1 |
| Gross profit | 0 | 1 |
| Research and development | 1 | 1 |
| Selling, general and administrative | 5 | 3 |
| Total operating expenses | 6 | 4 |
| Operating income | (6) | (3) |
| Interest expense | 0 | 0 |
| Interest and investment income | 0 | 0 |
| Other non-operating income (expense) | 0 | (0) |
| Net income | (6) | (4) |